Jesse C Stewart1, Brittanny M Polanka, Kaku A So-Armah, Jessica R White, Samir K Gupta, Suman Kundu, Chung-Chou H Chang, Matthew S Freiberg. 1. From the Department of Psychology (Stewart, Polanka), Indiana University-Purdue University Indianapolis (IUPUI), Indianapolis, Indiana; Department of General Internal Medicine (So-Armah), Boston University School of Medicine, Boston, Massachusetts; Office of Epidemiology (White), Maricopa County Department of Public Health, Phoenix, Arizona; Division of Infectious Disease (Gupta), Indiana University School of Medicine, Indianapolis, Indiana; Division of Cardiovascular Medicine, Department of Medicine (Kundu, Freiberg), Vanderbilt University School of Medicine, Nashville, Tennessee; Department of Medicine (Chang), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and Tennessee Valley Geriatric Research Education and Clinical Centers (Freiberg), Nashville, Tennessee.
Abstract
OBJECTIVE: We sought to determine the associations of total, cognitive/affective, and somatic depressive symptoms and antidepressant use with biomarkers of processes implicated in cardiovascular disease in HIV (HIV-CVD). METHODS: We examined data from 1546 HIV-positive and 843 HIV-negative veterans. Depressive symptoms were assessed using the Patient Health Questionnaire-9, and past-year antidepressant use was determined from Veterans Affair pharmacy records. Monocyte (soluble CD14 [sCD14]), inflammatory (interleukin-6 [IL-6]), and coagulation (D-dimer) marker levels were determined from previously banked blood specimens. Linear regression models with multiple imputation were run to estimate the associations between depression-related factors and CVD-relevant biomarkers. RESULTS: Among HIV-positive participants, greater somatic depressive symptoms were associated with higher sCD14 (exp[b] = 1.02, 95% confidence interval [CI] = 1.00-1.03) and D-dimer (exp[b] = 1.06, 95% CI = 1.00-1.11) after adjustment for demographics and potential confounders. Further adjustment for antidepressant use and HIV factors slightly attenuated these relationships. Associations were also detected for antidepressant use, as selective serotonin reuptake inhibitor use was related to lower sCD14 (exp[b] = 0.95, 95% CI = 0.91-1.00) and IL-6 (exp[b] = 0.86, 95% CI = 0.76-0.96), and tricyclic antidepressant use was related to higher sCD14 (exp[b] = 1.07, 95% CI = 1.03-1.12) and IL-6 (exp[b] = 1.14, 95% CI = 1.02-1.28). Among HIV-negative participants, total, cognitive/affective, and somatic depressive symptoms were associated with higher IL-6, and tricyclic antidepressant use was related to higher sCD14. CONCLUSIONS: Our novel findings suggest that a) monocyte activation and altered coagulation may represent two pathways through which depression increases HIV-CVD risk and that b) tricyclic antidepressants may elevate and selective serotonin reuptake inhibitors may attenuate HIV-CVD risk by influencing monocyte and inflammatory activation.
OBJECTIVE: We sought to determine the associations of total, cognitive/affective, and somatic depressive symptoms and antidepressant use with biomarkers of processes implicated in cardiovascular disease in HIV (HIV-CVD). METHODS: We examined data from 1546 HIV-positive and 843 HIV-negative veterans. Depressive symptoms were assessed using the Patient Health Questionnaire-9, and past-year antidepressant use was determined from Veterans Affair pharmacy records. Monocyte (soluble CD14 [sCD14]), inflammatory (interleukin-6 [IL-6]), and coagulation (D-dimer) marker levels were determined from previously banked blood specimens. Linear regression models with multiple imputation were run to estimate the associations between depression-related factors and CVD-relevant biomarkers. RESULTS: Among HIV-positive participants, greater somatic depressive symptoms were associated with higher sCD14 (exp[b] = 1.02, 95% confidence interval [CI] = 1.00-1.03) and D-dimer (exp[b] = 1.06, 95% CI = 1.00-1.11) after adjustment for demographics and potential confounders. Further adjustment for antidepressant use and HIV factors slightly attenuated these relationships. Associations were also detected for antidepressant use, as selective serotonin reuptake inhibitor use was related to lower sCD14 (exp[b] = 0.95, 95% CI = 0.91-1.00) and IL-6 (exp[b] = 0.86, 95% CI = 0.76-0.96), and tricyclic antidepressant use was related to higher sCD14 (exp[b] = 1.07, 95% CI = 1.03-1.12) and IL-6 (exp[b] = 1.14, 95% CI = 1.02-1.28). Among HIV-negative participants, total, cognitive/affective, and somatic depressive symptoms were associated with higher IL-6, and tricyclic antidepressant use was related to higher sCD14. CONCLUSIONS: Our novel findings suggest that a) monocyte activation and altered coagulation may represent two pathways through which depression increases HIV-CVD risk and that b) tricyclic antidepressants may elevate and selective serotonin reuptake inhibitors may attenuate HIV-CVD risk by influencing monocyte and inflammatory activation.
Authors: Kathleen A McGinnis; Cynthia A Brandt; Melissa Skanderson; Amy C Justice; Shahida Shahrir; Adeel A Butt; Sheldon T Brown; Matthew S Freiberg; Cynthia L Gibert; Matthew Bidwell Goetz; Joon Woo Kim; Margaret A Pisani; David Rimland; Maria C Rodriguez-Barradas; Jason J Sico; Hilary A Tindle; Kristina Crothers Journal: Nicotine Tob Res Date: 2011-09-12 Impact factor: 4.244
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Amy C Justice; Kathleen A McGinnis; J Hampton Atkinson; Robert K Heaton; Corinna Young; Joseph Sadek; Tamra Madenwald; James T Becker; Joseph Conigliaro; Sheldon T Brown; David Rimland; Steve Crystal; Michael Simberkoff Journal: AIDS Date: 2004-01-01 Impact factor: 4.177
Authors: A Norcini Pala; P Steca; R Bagrodia; L Helpman; V Colangeli; P Viale; M L Wainberg Journal: Brain Behav Immun Date: 2016-02-13 Impact factor: 7.217
Authors: K Schroecksnadel; M Sarcletti; C Winkler; B Mumelter; G Weiss; D Fuchs; G Kemmler; R Zangerle Journal: Brain Behav Immun Date: 2008-02-07 Impact factor: 7.217
Authors: Rita Haapakoski; Julia Mathieu; Klaus P Ebmeier; Harri Alenius; Mika Kivimäki Journal: Brain Behav Immun Date: 2015-06-09 Impact factor: 7.217
Authors: Adam W Carrico; Emily M Cherenack; Leah H Rubin; Roger McIntosh; Delaram Ghanooni; Jennifer V Chavez; Nichole R Klatt; Robert H Paul Journal: Psychosom Med Date: 2022-08-28 Impact factor: 3.864
Authors: Heather M Derry; Carrie D Johnston; Chelsie O Burchett; Mark Brennan-Ing; Stephen Karpiak; Yuan-Shan Zhu; Eugenia L Siegler; Marshall J Glesby Journal: J Gerontol B Psychol Sci Soc Sci Date: 2022-01-12 Impact factor: 4.077
Authors: Jordan N Kohn; Matthew Shane Loop; Julie J Kim-Chang; Patricia A Garvie; John W Sleasman; Bernard Fischer; H Jonathon Rendina; Steven Paul Woods; Sharon L Nichols; Suzi Hong Journal: J Acquir Immune Defic Syndr Date: 2021-06-01 Impact factor: 3.771
Authors: Brittanny M Polanka; Suman Kundu; Kaku A So-Armah; Matthew S Freiberg; Samir K Gupta; Tamika C B Zapolski; Adam T Hirsh; Roger J Bedimo; Matthew J Budoff; Adeel A Butt; Chung-Chou H Chang; Stephen S Gottlieb; Vincent C Marconi; Julie A Womack; Jesse C Stewart Journal: PLoS One Date: 2021-02-09 Impact factor: 3.752